Veozah™- the first non-hormonal medication now approved to Treat Moderate to Severe Hot Flashes Caused by Menopause

Hot flashes occur in about 80% of menopausal women and are characterized by a sudden feeling of intense warmth that can include sweating, chills and flushing lasting anywhere from one to five minutes or longer. Women commonly report the interruption of daily living and extreme uncomfort that accompany hot flashes. With the help of available treatment options, women are able to reduce symptoms and live better quality lives.

Clinical Research Philadelphia is proud to have participated in 4 clinical trials aiming at addressing Menopause. These efforts have led to the approval of Veozah™ (fezolinetant), an oral non-hormonal medication used for the treatment of hot flashes in menopausal women. This non-hormonal medication is a first-in-class treatment option for women experiencing hot flashes including those who do not qualify for hormone therapies currently used as treatment.

Veozah™ is unique in its approach because unlike other hormone therapies, it targets receptors in the brain that control the regulation of body temperature. Because of its non-hormonal approach, even women with a history of vaginal bleeding, heart attacks, blood clots,etc. may qualify for this treatment.

Clinical Research Philadelphia is proud of its commitment to Women’s Health. CRP is helping drive the future of medicine. Be a part of that change- the future of medicine begins with you.